A 69-year-old Caucasian man presented with a lesion on his forehead which "grew overnight" (Figure 1 ). It was located at the edge of a scar of a previously removed squamous cell carcinoma. Th e patient has had numerous squamous cell carcinomas and mild hyperlipidemia.
What is your diagnosis?
Over the ensuing week, the patient developed two fresh ulcers on his forehead "overnight" (Figure 2 ). Th ere was no erythema, fl aking, pain, numbness, or tingling in the areas prior to the development of the ulcers. Th e two new lesions were tender. Th ere was no known trauma. Now, what is your diagnosis? DIAGNOSIS: Herpes zoster.
Herpes zoster is the reactivation of varicella zoster virus. It typically presents with a prodrome of pain, tingling, or tenderness, and then an eruption of grouped vesicles on an erythematous base occurs within a sensory dermatome. Th e most common complication is postherpetic neuralgia, which is a neuropathic pain syndrome that develops after the rash has resolved (1-3). It is typically described as burning, stabbing, or shocklike pain in the area where the rash was located (1, 4) . Postherpetic neuralgia occurs in 14% to 20% of patients with herpes zoster (2).
An unusual facial ulcer
Amanda Abramson, MD, and Alan Menter, MD Dermatology Report A vaccine for the prevention of herpes zoster and postherpetic neuralgia, Zostavax, was approved by the Food and Drug Administration in 2006 (5). It is a live virus vaccine composed of at least 19,400 plaque-forming units of the Oka/Merck strain of the varicella zoster virus. Th e potency of this vaccine is 14-fold higher than that used in children (2) . Zostavax reduces the risk of developing herpes zoster by 51% and decreases the incidence of postherpetic neuralgia by 67% (3, 4) ; further, it decreases the burden of illness of herpes zoster by 61% and decreases the duration of postherpetic neuralgia by 57% (3, 4) . Th erefore, disease severity is decreased in patients who experience a herpes zoster outbreak despite vaccination (3, 4) . Most recently, Zostavax was shown to decrease the risk of ophthalmic involvement, therefore decreasing the risk of serious vision-threatening sequelae (4). Zostavax is recommended by the Centers for Disease Control and Prevention for use in patients >60 years of age who are not immunocompromised (3, 4) .
Our patient had received the Zostavax vaccine 2 weeks prior to his initial presentation. Th e patient is otherwise healthy and is not immunocompromised. To date, there are no reports of the Zostavax Oka/Merck varicella virus strain causing herpes zoster itself. However, there are reports of a herpes zoster-like reaction occurring at an average of 16 days after vaccination (4, 6) . Wild-type varicella zoster virus DNA was isolated by polymerase chain reaction from the active lesions of the vaccinated patients with a herpes zoster-like reaction, confi rming the reactions were likely not due to the vaccine (6). Th us, our patient experienced a herpes zoster-like reaction from the vaccine given 2 weeks prior to the onset of his facial lesions.
Th e case highlights the importance of conducting a thorough history, including a vaccination history. It exemplifi es how a vaccine-dampened outbreak of herpes zoster can clinically mimic nonmelanoma skin cancer. Th erefore, truncated herpes zoster should be included in the diff erential diagnosis for nonmelanoma skin cancer for recently vaccinated individuals; a biopsy of the lesion is necessary for confi rmation of disease.
